Article
A critical review of the United States regulatory pathways for determining the equivalence…
Drug Design, Development and Therapy · 2020 · Kim S, Kim S, Lee H
Key facts
| Title | A critical review of the United States regulatory pathways for determining the equivalence of efficacy between CT-P13 and original infliximab (Remicade®) |
|---|---|
| First author | Kim S, Kim S, Lee H |
| Journal | Drug Design, Development and Therapy |
| Published | Jul 17, 2020 |
| DOI | 10.2147/DDDT.S254776 |
| Devices mentioned | 761086 |
At a glance
- 1–9 FDA submissions mentioned
- None Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1